Bacterial meningitis in diabetes patients: a population-based prospective study

Kiril E. B. van Veen1,2, Matthijs C. Brouwer1, Arie van der Ende3 & Diederik van de Beek1

Diabetes mellitus is associated with increased infection rates. We studied clinical features and outcome of community-acquired bacterial meningitis in diabetes patients. Patients were selected from a nationwide, prospective cohort on community-acquired bacterial meningitis performed from March 2006 to October 2014. Data on patient history, symptoms and signs on admission, treatment, and outcome were prospectively collected. A total of 183 of 1447 episodes (13%) occurred in diabetes patients. The incidence of bacterial meningitis in diabetes patients was 3.15 per 100,000 patients per year and the risk of acquiring bacterial meningitis was 2.2-fold higher for diabetes patients. S. pneumoniae was the causative organism in 139 of 183 episodes (76%) and L. monocytogenes in 11 of 183 episodes (6%). Outcome was unfavourable in 82 of 183 episodes (45%) and in 43 of 183 episodes (23%) the patient died. Diabetes was associated with death with an odds ratio of 1.63 (95% CI 1.12–2.37, P = 0.011), which remained after adjusting for known predictors of death in a multivariable analysis (OR 1.98 [95% CI 1.13–3.48], P = 0.017). In conclusion, diabetes is associated with a 2-fold higher risk of acquiring bacterial meningitis. Diabetes is a strong independent risk factor for death in community-acquired adult bacterial meningitis.

Diabetes mellitus type 1 and 2 have been associated with increased infection rates1, particularly bacterial infections2. Diabetes has been associated with a risk ratio of 1.21 for development of infection, and a risk ratio of 2.17 for hospitalization for infection2. Infections in diabetes patients are also more likely to be severe than in the non-diabetes persons3. Diabetes has been stated as risk for bacterial meningitis, in particular listeria meningitis although few studies have been done4–10. Retrospective studies have described diabetes to be associated with higher mortality rates among meningitis patients5,6. However, these studies were either retrospective and included only few patients4–6, or did not have diabetes as the focus of the article7–10. Therefore, little is known about bacterial meningitis in diabetes patients. We compared clinical features, outcome, and causative pathogens of community-acquired bacterial meningitis in patients with and without diabetes in a nationwide prospective cohort study.

Methods
We conducted a nationwide, prospective cohort study on community-acquired bacterial meningitis. Methods have been described in detail previously11. Between March 2006 and October 2014, patients with bacterial meningitis over 16 years old were included. Bacterial meningitis was defined as a positive cerebrospinal fluid (CSF) culture or as a the combination of a positive blood culture with a relevant pathogen, or positive PCR or antigen test in cerebrospinal fluid for Streptococcus pneumoniae or Neisseria meningitidis, with at least one specific CSF finding predictive of bacterial meningitis consisting of a CSF leukocyte count >2000 cells/mm3, polymorphonuclear leukocyte count >1180 cells/mm3, glucose level <1.9 mmol/L, protein level >2 g/L, or CSF/blood glucose ratio <0.2312. Patients with a neurosurgical device, neurosurgical operation or procedure, and patients with neurotrauma within 1 month of the onset of meningitis were excluded from the cohort. Data on patient history, symptoms and signs on admission, laboratory findings, radiologic examination, treatment, and outcome were prospectively collected by means of a case record form (CRF). The CRF included a standard question on presence

1Department of Neurology, Amsterdam Neuroscience, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 2Department of Neurology, Medical Center Haaglanden, The Hague, the Netherlands. 3The Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Correspondence and requests for materials should be addressed to D.v.d.B. (email: d.vandebeek@amc.uva.nl)
of diabetes in the medical history. In addition, all discharge letters were screened for a history of diabetes. We selected all patients reported to have diabetes by either the CRF or discharge letter. All patients underwent neurologic examination at hospital discharge, and outcome was graded using the Glasgow Outcome Scale. A favourable outcome was defined as a score of 5, and an unfavourable outcome was defined as a score of 1 to 4. Focal neurologic abnormalities were divided into focal cerebral deficits (e.g. aphasia, monoparesis, or hemiparesis) and cranial nerve palsies.

The criteria of the American Diabetes Association were used to define hypoglycaemia and hyperglycaemia. A blood glucose level of <3.9 mmol/L (<70 mg/dL) was defined as hypoglycaemia, a non-fasting blood glucose levels of >7.8 mmol/L (>140 mg/dL) as hyperglycaemia, and a non-fasting blood glucose levels of >11.1 mmol/L (>200 mg/dL) as severe hyperglycaemia. Glycosylated haemoglobin (HbA1C) was not measured in the patients and no information on formal glucose tolerance testing was available.

The study period from January 2007 till January 2014 was used to determine the incidence of bacterial meningitis in the people with and without diabetes. The prevalence of diabetes in the Netherlands was obtained from the National Public Health Compass, which estimated the point prevalence for January first, 2011. This prevalence was calculated for all diabetic patients and with stratification according to age group (17–39, 40–64, >65 years old). Data on the general population was derived from Statistics Netherlands (statline.cbs.nl).

**Ethical Statement.** The MeninGene study was approved by the ethics committee of the Academic Medical Center, Amsterdam, The Netherlands. Ethical approval was granted in all participating centers and written informed consent was obtained from all participating individuals or legally authorized representatives. The study was conducted according to the principles of the Declaration of Helsinki (version of 2013, Fortaleza, Brazil) and in accordance with the Medical Research Involving Human Subjects Act (WMO) and other guidelines, regulations and acts.

**Statistics.** Statistical analyses were performed with the use of SPSS statistical software, version 23 (SPSS Inc). For numerical and ordinal data the student t-test or Mann-Whitney U test were used. For categorical data the Fisher exact test was used. Logistic regression was used to examine the association between potential predictors and the likelihood of an unfavourable outcome and of death. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to quantify the strength of these associations. Possible predictors of an unfavourable outcome and death were chosen on the basis of previous research. The 95%-confidence interval (95%CI) for the incidence was calculated by using the Poisson distribution. All tests were 2-tailed, and p < 0.05 was considered significant.

**Results**

A total of 1447 episodes of bacterial meningitis were included in the cohort between March 2006 and October 2014. A total of 183 episodes (13%) in 179 patients were reported to occur in diabetes patients. In 16 episodes no data on diabetes presence or absence could be obtained and these episodes were excluded from the analysis. Two diabetes patients had three episodes of pneumococcal meningitis during the study period of which one had a history of late onset agammaglobulinaemia next to diabetes.

In 2011, the estimated point prevalence of diabetes mellitus in the Netherlands was 834,000. The incidence of bacterial meningitis in diabetes patients over 16-years old in the Netherlands was 3.15 per 100,000 patients per year (95% confidence incidence [CI] 2.73–3.64).

The incidence bacterial meningitis in persons over 16-years old without diabetes in the Netherlands was 1.44 per 100,000 persons per year (95% CI 1.36–1.52). The risk of acquiring bacterial meningitis was therefore 2.2-fold higher for diabetes patients (95% CI 1.9–2.6; P < 0.001).

The incidence of bacterial meningitis was 2.39 per 100,000 patients per year (95% CI 0.99–5.74) for diabetes patients between 17 and 40-years old, 3.43 (95% CI 2.76–4.28) for patients between 40 and 65-years old and 3.00 (95% CI 2.76–3.25) for patients over 65-years old. For non-diabetes persons the corresponding incidences were 0.70 (95% CI 0.61–0.79), 1.50 (95% CI 1.38–1.62) and 2.96 (95% CI 2.69–3.25) per 100,000 persons per year respectively. The risk of acquiring bacterial meningitis was 3.4-fold higher (95% CI 1.4–8.3; P = 0.007) for diabetes patients between 17 and 40-years old and 2.3-fold higher (95% CI 1.8–2.9; P < 0.001) for diabetes patients between 40 and 65-years old compared to their non-diabetes counterparts. No difference in risk was found for patients over 65-years old (1.0 [95% CI 0.13–1.26]; P = 0.903).

The median age of patients with diabetes and community-acquired bacterial meningitis was 65 years (range 25–91 years, Table 1). Type of diabetes mellitus was recorded for 87 episodes (48%), all of which were in type 2 diabetes patients. In 68 episodes (37%), patients used oral antidiabetic agents, in 16 episodes (9%) the combination of oral antidiabetic agents and insulin, and in 13 episodes (7%) insulin. Type of anti-diabetic agents was unknown in 86 episodes (47%). Conditions increasing the risk of bacterial meningitis, other than diabetes, were present in 44 of 183 episodes (24%) and consisted mostly of cancer (18 episodes), the use of immunosuppressive drugs (16 episodes), and alcoholism (12 episodes). Nine of these patients had more than one other predisposing factor. A distant focus of infection was present in 87 of 171 episodes (51%), with otitis or sinusitis (69 episodes; 38%) and pneumonia (22 episodes; 13%) as most frequently encountered distant foci.

**Clinical features.** Headache was present in 117 of 148 episodes (79%), and an altered mental state (defined by a Glasgow Coma Scale score below 14) was present on admission in 148 of 183 episodes (81%). Neck stiffness occurred in 125 of 173 episodes (72%) and fever (defined by a temperature of 38°C or higher) in 144 of 181 episodes (80%). Symptoms and signs at presentation did not differ from non-diabetes bacterial meningitis patients.

**Statistics.**
Blood chemistry tests showed diabetes patients had elevated whole blood leukocyte counts (median 16.3 × 10^9/L [interquartile range (IQR) 11.6–22.6 × 10^9/L]) and C-reactive protein was elevated (>8.0 mmol/L) in 169 of 173 episodes (98%; median 172 mg/L [IQR 71–298 mg/L]). Leukocyte count and C-reactive protein levels did not differ between patients with and without diabetes. Upon presentation hyperglycaemia was present in 158 of 175 episodes (90%). Median blood glucose level was 12.6 mmol/L (IQR 10.2–16.0 mmol/L). Severe hyperglycaemia was more often present in diabetes patients compared to patients without diabetes (118 of 175 [67%] vs. 256 of 1191 [21%], P < 0.001).

A lumbar puncture was performed in all patients. Independent predictors of bacterial meningitis were present in 160 of 183 episodes (87%). Median CSF leukocyte count was 3,300 cells/mm³ (IQR 1,006–7,500 cells/mm³) and in 44 of 177 episodes (25%) CSF leukocyte count was below 1,000 cells/mm³. Each analysis showed signs of sinusitis or otitis, in seven of 156 episodes (4%) generalized brain oedema, in five of 155 episodes (3%) hydrocephalus and in six of 155 (4%) a hypodense lesion consistent with cerebral infarction was found.

S. pneumoniae was the causative organism in 139 of 183 episodes (76%), L. monocytogenes in 11 of 183 episodes (6%), and N. meningitidis in 10 of 183 episodes (5%; Table 1). Meningococcal meningitis was less often encountered in diabetes patients as compared to the non-diabetes meningitis patients (10 of 183 [5%] vs. 137 of 1248 [11%]; P = 0.019). Pseudomonas aeruginosa (in two patients) and Nocardia farcinica (in one patient) were identified only in diabetes patients.

### Table 1. Characteristics of diabetes patients with bacterial meningitis.

| Characteristic                                | n/N (%)                     | Characteristic                                | n/N (%)                     |
|-----------------------------------------------|------------------------------|-----------------------------------------------|------------------------------|
| Age (years)                                   | 65 (25–91)                  | Blood chemistry tests                        |                             |
| Female                                        | 85/183 (46)                 | Leukocyte count (x10^9/L)                     | 16.3 (2.5–41.9)             |
| Diabetes mellitus type 2                      | 87/183 (48)                 | Thrombocytes (x10^9/L)                       | 208 (39–868)                |
| Type unknown/not reported                     | 96/183 (52)                 | C-reactive protein (mg/L)                     | 172 (4–736)                 |
| Predisposing conditions^b                     | 44/183 (24)                 | Glucose (mmol/L)                             | 12.6 (1.5–30.9)             |
| Cancer                                        | 18/181 (10)                 | Indexes of inflammation in CSF^e             |                             |
| Immunosuppressive drugs                       | 16/182 (9)                  | Leukocyte count (cells/mm³)                   | 3,300 (1–75,000)            |
| Alcoholism                                     | 12/166 (7)                  | Protein (g/L)                                | 4.31 (0.44–19.70)           |
| Distant loci of infection                     | 87/171 (51)                 | CSF/blood glucose ratio                       | 0.16 (0.0–1.55)             |
| Otitis media or sinusitis                     | 69/182 (38)                 | Causative organism                           |                             |
| Pneumonia                                      | 22/170 (13)                 | Streptococcus pneumoniae                     | 139/183 (76)                |
| Symptoms and signs on admission               |                              | Listeria monocytogenes                       | 11/183 (6)                  |
| Duration of symptoms >24 h                    | 88/171 (51)                 | Neisseria meningitidis                       | 10/183 (5)                  |
| Headache                                      | 117/148 (79)                | Escherichia coli                             | 4/183 (2)                   |
| Nausea                                        | 81/140 (58)                 | Streptococcus species                        | 10/183 (5)                  |
| Temperature ≥38°C                             | 144/181 (80)                | Staphylococcus aureus                        | 2/183 (1)                   |
| Neck stiffness                                | 125/173 (72)                | Staphylococcus epidermidis                    | 1/183 (1)                   |
| Triad^c                                       | 86/173 (50)                 | Haemophilus influenza                        | 2/183 (1)                   |
| Signs of septic shock                         | 56/177 (32)                 | Pseudomonas aeruginosa                       | 2/183 (1)                   |
| Seizures                                      | 8/170 (5)                   | Nocardia farcinica                           | 1/183 (1)                   |
| Altered mental state (EMV <14)                | 148/183 (81)                | Klebsiella pneumoniae                        | 1/183 (1)                   |
| Coma (EMV <8)                                 | 30/183 (16)                 | Outcome                                      |                             |
| Focal neurological deficits                   | 57/181 (31)                 | Unfavorable outcome                          | 82/183 (45)                 |
| Cranial nerve palsy                           | 15/154 (10)                 | Mortality                                    | 43/183 (23)                 |
| Brain imaging                                 | 165/183 (90)                | Neurological sequelae                        | 49/122 (40)                 |
| Abnormal                                      | 65/165 (39)                 | Hearing loss                                 | 16/124 (13)                 |
| Otitis or sinusitis on CT/MRI                 | 50/165 (30)                 |                                             |                             |

Blood chemistry tests showed diabetes patients had elevated whole blood leukocyte counts (median 16.3 × 10^9/L [interquartile range (IQR) 11.6–22.6 × 10^9/L]) and C-reactive protein was elevated (>8.0 mmol/L) in 169 of 173 episodes (98%; median 172 mg/L [IQR 71–298 mg/L]). Leukocyte count and C-reactive protein levels did not differ between patients with and without diabetes. Upon presentation hyperglycaemia was present in 158 of 175 episodes (90%). Median blood glucose level was 12.6 mmol/L (IQR 10.2–16.0 mmol/L). Severe hyperglycaemia was more often present in diabetes patients compared to patients without diabetes (118 of 175 [67%] vs. 256 of 1191 [21%], P < 0.001).

A lumbar puncture was performed in all patients. Independent predictors of bacterial meningitis were present in 160 of 183 episodes (87%). Median CSF leukocyte count was 3,300 cells/mm³ (IQR 1,006–9,860 cells/mm³) and in 44 of 177 episodes (25%) CSF leukocyte count was below 1,000 cells/mm³.

Neuroimaging (computed tomography) was performed on admission in 165 of 183 episodes (90%). In 50 of 165 episodes (30%) imaging showed signs of sinusitis or otitis, in seven of 156 episodes (4%) generalized brain oedema, in five of 155 episodes (3%) hydrocephalus and in six of 155 (4%) a hypodense lesion consistent with cerebral infarction was found.

S. pneumoniae was the causative organism in 139 of 183 episodes (76%), L. monocytogenes in 11 of 183 episodes (6%), and N. meningitidis in 10 of 183 episodes (5%; Table 1). Meningococcal meningitis was less often encountered in diabetes patients as compared to the non-diabetes meningitis patients (10 of 183 [5%] vs. 137 of 1248 [11%]; P = 0.019). Pseudomonas aeruginosa (in two patients) and Nocardia farcinica (in one patient) were identified only in diabetes patients.

### Complications and outcome.

Neurological complications during admission in diabetes patients consisted of seizures in 28 of 172 episodes (16%), cerebrovascular accidents in 23 of 169 episodes (14%), hydrocephalus in 5 of 164 episodes (3%) and sinus thrombosis in 2 of 162 episodes (1%). Neurological complications did not differ between patients with and without diabetes.
Cardiorespiratory failure occurred in 84 of 179 episodes (47%) and was more common in diabetes patients as compared to the patients without diabetes (84 of 179 [47%] vs. 453 of 1212 [37%]; \(P = 0.017\)). Admission to the intensive care unit was similar in patients with and without diabetes (98 of 183 [54%] vs. 615 of 1248 [49%]; \(P = 0.304\)), but diabetes patients more often had respiratory failure (57 of 176 [32%] vs. 300 of 1204 [25%], \(P = 0.042\)) and need of mechanical ventilation (71 of 176 [40%] vs. 391 of 1197 [33%], \(P = 0.049\)) compared to patients without diabetes.

Outcome was unfavourable in 82 of 183 episodes (45%) of bacterial meningitis in diabetes patients and in 43 of 183 episodes (23%) of the patient died. In univariable analysis diabetes mellitus was associated with death with an OR of 1.63 (95% CI 1.12–2.37, \(P = 0.011\); Table 3). The effect size of diabetes for death remained after adjusting for known predictors of death (age, otitis and sinusitis, neck stiffness, score on GCS, blood thrombocyte count, CRP, CSF leukocyte count, CSF protein, \(L.\) monocytogenes, \(S.\) pneumoniae), blood glucose and treatment with adjunctive dexamethasone in a multivariable analysis (OR 1.98 [95% CI 1.13–3.48], \(P = 0.017\)).

Antimicrobial and adjunctive dexamethasone therapy. Initial antimicrobial therapy was reported for 180 of 183 episodes (98%) and included a combination of amoxicillin or penicillin and third-generation cephalosporin in 99 episodes (55%), monotherapy third-generation cephalosporin in 42 episodes (23%), monotherapy amoxicillin or penicillin in 37 episodes (21%), and other in two episodes (1%). Inadequate initial antimicrobial therapy was started in four listerial meningitis episodes consisting of monotherapy with a third-generation cephalosporin. In seven episodes patients (4%) were treated additionally with acyclovir on the suspicion of viral encephalitis.

Adjuvant dexamethasone in diabetes patients was initiated before or together with the antibiotics in 139 of 183 episodes (77%) and in 134 of 181 episodes (74%) given according to guideline recommendations (10 mg four times per day for 4 days, administered before or together with the antibiotics)19. Fewer diabetes patients with meningitis received dexamethasone compared to non-diabetes meningitis patients (139 of 181 [77%] vs. 1095 of 1203 [91%]; \(p < 0.001\)). Unfavourable outcome was observed in 57 of 136 episodes (42%) of patients treated with adjunctive dexamethasone and 29 of 136 patients (21%) died. Outcome (favourable or unfavourable) and mortality did not differ between diabetes patients treated with and without dexamethasone (79 of 136 [58%] vs. 20 of 45 [44%], \(P = 0.123\) and 29 of 136 [21%] vs. 14 of 45 [31%], \(P = 0.225\)). During dexamethasone treatment

| Characteristic | Diabetes mellitus + | Diabetes mellitus − | \(P\)-value |
|---------------|---------------------|---------------------|------------|
| Age (years)   | 65 (25–91)          | 60 (17–94)          | <0.001     |
| Female        | 85/183 (46)         | 617/1248 (49)       | 0.477      |

Table 2. Comparison between patients with and without diabetes mellitus*. CSF: cerebrospinal fluid. \(P\) values < 0.05 are giving in bold. *Data are presented as n/N (%), or median (range). †Other than immunosuppressive drugs.
before or together with the antibiotics, in bacterial meningitis patients, including those with diabetes 18,25,28. In empiric treatment for diabetes patients must include ampicillin or amoxicillin to cover listeria22,23. L. monocytogenes related to poor outcome20. This effect could not be explained by high blood glucose levels, which has previously been of polymorphonuclear leukocytes, monocytes and lymphocytes, which have all been associated with degree and to an immunocompromised state by decreased efficacy of cell-mediated immunity, with relatively malfunction

The current study showed that causative pathogens between diabetes and non-diabetes meningitis patients are similar. Guidelines recommend starting 10 mg of dexamethasone four times per day for four days, administered before or together with the antibiotics, in bacterial meningitis patients, including those with diabetes18,25,28. In

### Discussion

Diabetes patients are at 2-fold higher risk for bacterial meningitis as compared than non-diabetes patients. This is in line with previous retrospective studies describing diabetes as a risk factor for bacterial infections4–2. Our study was prospective and performed nationwide in the Netherlands (population, 16 million). Diabetes may lead to an immunocompromised state by decreased efficacy of cell-mediated immunity, with relatively malfunction of polymorphonuclear leukocytes, monocytes and lymphocytes, which have all been associated with degree and duration of hyperglycaemia in patients1,9. We also found that diabetes is an independent predictor of mortality in bacterial meningitis. This effect could not be explained by high blood glucose levels, which has previously been related to poor outcome30. The distributions of pathogens between diabetes and non-diabetes patients were similar. Most common cause among diabetes patients was S. pneumoniae (76%), followed by L. monocytogenes (6%) Diabetes patients have previously been described to be at particular high risk for listeria meningitis. Our data show that at least in Netherlands this is not the case. Some uncommon pathogens, such as Pseudomonas aeruginosa and Nocardia farcinica, were identified in diabetes patients only. Our findings are in contrast to studies from Korea and Taiwan, describing K. pneumoniae as causative pathogen in two-thirds of diabetes patients with meningitis4,5,10. However, this can be explained by differences in general epidemiology of infectious diseases between the continents11. As L. monocytogenes is the second most common causative organism in diabetes patients identified in our cohort, empiric treatment for diabetes patients must include ampicillin or amoxicillin to cover listeria22,23.

Diabetes patients were less likely to be treated with adjunctive dexamethasone therapy. Physicians may be hesitant to administer corticosteroids in diabetes patients. First, administration of corticosteroids in diabetes patients may cause dysregulation of diabetes. This did occur, but only in 13% of diabetes patients on dexamethasone. Although hyperglycaemia has been associated with unfavourable outcome in bacterial meningitis7, this detrimental effect probably does not counterbalance the favourable effect of adjunctive dexamethasone in pneumococcal meningitis24–27. Second, patients with diabetes have been described to be at risk for atypical pathogens. The effect of adjunctive dexamethasone therapy was mainly driven by the effect in the pneumococcal subgroup24–27. The current study showed that causative pathogens between diabetes and non-diabetes meningitis patients are similar. Guidelines recommend starting 10 mg of dexamethasone four times per day for four days, administered before or together with the antibiotics, in bacterial meningitis patients, including those with diabetes18,25,28. In

### Table 3. Univariable and multivariable analyses in patients with bacterial meningitis on risk factors for death. CRP: C-reactive protein, CSF: cerebrospinal fluid, GCS: Glasgow coma scale. P values < 0.05 are giving in bold.

| Variable                        | Univariable analysis | Multivariable analysis |
|---------------------------------|----------------------|-----------------------|
|                                 | OR (95% CI)          | P value | OR (95% CI) | P value |
| Diabetes mellitus               | 1.63 (1.12–2.37)     | 0.011    | 1.98 (1.13–3.48) | 0.017 |
| Blood glucose                   |                      |          |            |        |
| Normal (3.9–7.8 mmol/L)         | Reference            |          | Reference  |        |
| Low (<3.9 mmol/L)               | 2.22 (0.40–12.35)    | 0.363    | 0.43 (0.06–3.08) | 0.430 |
| High (>7.8–11, 1 mmol/L)        | 0.67 (0.47–0.95)     | 0.023    | 0.64 (0.40–1.05) | 0.076 |
| Severe high (>11, 1 mmol/L)     | 1.09 (0.76–1.58)     | 0.640    | 0.84 (0.47–1.48) | 0.538 |
| Adjunctive dexamethasone        | 0.40 (0.30–0.55)     | <0.001   | 0.62 (0.40–0.97) | 0.035 |
| Age                             | 1.05 (1.04–1.06)     | <0.001   | 1.04 (1.02–1.05) | <0.001 |
| Otitis or sinusitis             | 0.40 (0.29–0.57)     | <0.001   | 0.58 (0.37–0.93) | 0.022 |
| Neck stiffness                  | 0.50 (0.37–0.69)     | <0.001   | 0.51 (0.34–0.78) | 0.002 |
| Score on GCS                    | 0.84 (0.80–0.88)     | <0.001   | 0.85 (0.79–0.90) | <0.001 |
| Blood thrombocyte count         |                      |          |            |        |
| <150 × 10^12/L                  | 2.18 (1.60–2.97)     | <0.001   | 1.35 (0.87–2.08) | 0.178 |
| 150–450 × 10^12/L               | Reference            |          | Reference  |        |
| >450 × 10^12/L                  | 2.84 (1.21–6.66)     | 0.016    | 2.32 (0.56–9.66) | 0.247 |
| CRP (per 10 mg/l)               | 1.04 (1.03–1.05)     | <0.001   | 1.04 (1.02–1.05) | <0.001 |
| CSF leukocyte count             |                      |          |            |        |
| <100 cells/mm<sup>3</sup>       | Reference            |          | Reference  |        |
| 100–999 cells/mm<sup>3</sup>   | 0.48 (0.31–0.74)     | 0.001    | 0.58 (0.32–1.04) | 0.067 |
| 1000–10,000 cells/mm<sup>3</sup> | 0.19 (0.12–0.29)     | <0.001   | 0.28 (0.15–0.51) | <0.001 |
| >10,000 cells/mm<sup>3</sup>    | 0.20 (0.12–0.34)     | <0.001   | 0.25 (0.12–0.53) | <0.001 |
| CSF protein (g/L)               | 1.09 (1.05–1.13)     | <0.001   | 1.09 (1.04–1.15) | 0.001 |
| Listeria monocytogenes          | 2.76 (1.70–4.50)     | <0.001   | 1.99 (0.85–4.64) | 0.114 |
| Streptococcus pneumoniae        | 1.03 (0.76–1.39)     | 0.869    | 0.87 (0.51–1.49) | 0.617 |

hyperglycaemia requiring insulin was reported in 17 episodes (13%). One gastro-intestinal bleeding was reported after the use of dexamethasone, but despite the bleeding the patient had a good recovery.
non-pneumococcal bacterial meningitis patients with and without diabetes, dexamethasone should be carefully considered on an individual patient basis.

Our study has several limitations. The observational design of the study is sensitive to the introduction of confounding factors, which hinder the evaluation of the risk analysis. Although the incidence of diabetes mellitus in the Netherlands was estimated, this was done by a reliable source. Estimation was made by the National Public Health Compass, which is a part of the National Institute of Public Health and the Environment, and was based on data provided by the Netherlands Institute for Health Services Research to which most general practices are connected. Some specific information on diabetes patients was collected retrospectively, e.g. type of diabetes, diabetes treatment, and complications of the use of dexamethasone. This might lead to an underestimation of the complications associated with dexamethasone. Other limitations of this study were that only patients with culture-proven meningitis were included in our cohort study. Not all patients with suspected bacterial meningitis may undergo a lumbar puncture, e.g. patients with coagulopathy due to sepsis or those with space-occupying lesions on cranial imaging. Signs of sepsis or mass effect on cerebral CT are well defined predictors for unfavourable outcome. Underrepresentation of these patients in our cohort, may lead to an underestimated of unfavourable outcome and mortality.

References

1. Müller, L. M. et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41, 281–288 (2005).
2. Shah, B. R. & Hux, J. E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26, 510–513 (2003).
3. Calvet, H. M. & Yoshikawa, T. T. Infections in diabetes. Infect Dis Clin North Am 15, 407–421, viii (2001).
4. Huang, C. R. et al. Community-acquired spontaneous bacterial meningitis in adult diabetic patients: an analysis of clinical characteristics and prognostic factors. Infection 30, 346–350 (2002).
5. Muli, J. M. et al. Meningitis in diabetic patients. Neuro Endocrinol Lett 28 Suppl 3, 28–29 (2007).
6. Petrovic, C. G. et al. Bacterial meningitis during sepsis in diabetic patient. Rev Med Clin Soc Med Nat Inst 117, 901–907 (2013).
7. Schut, E. S. et al. Hyperglycemia in bacterial meningitis: a prospective cohort study. BMC Infect Dis 9, 57 (2009).
8. Jung, J. et al. Comparison of the clinical characteristics and outcomes of Klebsiella pneumoniae and Streptococcus pneumoniae meningitis. Diagn Microbiol Infect Dis 82, 87–91 (2015).
9. Lai, W. A. et al. Clinical characteristics and prognosis of acute bacterial meningitis in elderly patients over 65: a hospital-based study. BMC Geriatr 11, 91 (2011).
10. Tsai, M. H. et al. Bacterial meningitis in young adults in Southern Taiwan: clinical characteristics and therapeutic outcomes. Infection 34, 2–8 (2006).
11. Bijlsma, M. W. et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis (2015).
12. Spanos, A., Harrell, F. E. Jr. & Durack, D. T. Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. JAMA 262, 2700–2707 (1989).
13. American Diabetes. A. Diagnosis and classification of diabetes mellitus. Diabetes Care 31 Suppl 1, S55–S60 (2008).
14. Workgroup on Hypoglycemia, A. D. A. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28, 1245–1249 (2005).
15. Baan, C. A., Poos, M. J. J. C., Uiters, E. & Savelliouk, M. Hoe vaak komt diabetes mellitus voor en hoeveel mensen sterven eraan? Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid (National Public Health Compass). RIVM. Bilthoven. (2014).
16. van de Beek, D. et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 351, 1849–1859 (2004).
17. Koopmans, M. M. et al. Listeria monocytogenes sequence type 6 and increased rate of unfavorable outcome in meningitis: epidemiologic cohort study. Clin Infect Dis 57, 247–253 (2013).
18. van de Beek, D. et al. ESACMD guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect (2016).
19. Pozzilli, P. & Leslie, R. D. Infections and diabetes: mechanisms and prospects for prevention. Diabet Med 11, 935–941 (1994).
20. Clement, S. et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27, 593–591 (2004).
21. Brouwer, M. C., Tunkel, A. R. & van de Beek, D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 23, 467–492 (2010).
22. Chaudhuri, A. et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol 15, 649–659 (2008).
23. Tunkel, A. R. et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39, 1267–1284 (2004).
24. de Gans, J., van de Beek, D. & European Dexamethasone in Adulthood Bacterial Meningitis Study. I. Dexamethasone in adults with bacterial meningitis. N Engl J Med 347, 1549–1556 (2002).
25. van de Beek, D., Brouwer, M. C., Thwaits, G. E. & Tunkel, A. R. Advances in treatment of bacterial meningitis. Lancet 380, 1693–1702 (2012).
26. van de Beek, D., de Gans, J., Mcintyre, P. & Prasad, K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 4, 139–143 (2004).
27. van de Beek, D. et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 9, 254–263 (2010).
28. van de Beek, D., de Gans, J., Tunkel, A. R. & Wijdicks, E. F. Community-acquired bacterial meningitis in adults. N Engl J Med 354, 44–53 (2006).
29. Bijlsma, M. W. et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis 16, 339–347 (2016).

Acknowledgements

This study has been funded by grants from the Netherlands Organization for Health Research and Development (ZonMw; NWO-Veni grant 2012 [916.13.078] to MB, NWO-Vidi grant 2010 [016.116.358] to DB), the Academic Medical Center (AMC Fellowship 2008 to DB), and the European Research Council (2011 ERC Starting Grant 281156 to DB). The Netherlands Reference Laboratory for Bacterial Meningitis is supported by the National Institute of Public Health and the Environmental Protection, Bilthoven.
Author Contributions
D.B. and A.E designed the research, D.B and M.B. performed the research; K.V. collected and analysed the data; K.V. wrote the manuscript, M.B., A.E. and D.B. reviewed/edited the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: van Veen, K. E. B. et al. Bacterial meningitis in diabetes patients: a population-based prospective study. Sci. Rep. 6, 36996; doi: 10.1038/srep36996 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016